tiprankstipranks
Trending News
More News >
XTL Biopharmaceuticals Ltd. Sponsored ADR (XTLB)
NASDAQ:XTLB

XTL Biopharmaceuticals Sponsored ADR (XTLB) AI Stock Analysis

Compare
105 Followers

Top Page

XT

XTL Biopharmaceuticals Sponsored ADR

(NASDAQ:XTLB)

Rating:39Underperform
Price Target:
XTL Biopharmaceuticals Ltd. shows considerable financial difficulties with persistent losses and weak cash flow. The technical analysis aligns with a bearish outlook, while valuation metrics highlight an unattractive investment at present. Although the stock has seen a recent price surge, the absence of earnings call details makes future performance uncertain.

XTL Biopharmaceuticals Sponsored ADR (XTLB) vs. SPDR S&P 500 ETF (SPY)

XTL Biopharmaceuticals Sponsored ADR Business Overview & Revenue Model

Company DescriptionXTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
How the Company Makes MoneyXTL Biopharmaceuticals generates revenue primarily through the development and commercialization of proprietary drug candidates targeting autoimmune diseases and cancer. The company may earn money from licensing agreements, milestone payments, and royalties related to its drug development programs. Key revenue streams include partnerships with other pharmaceutical companies for the co-development or out-licensing of its drug candidates, as well as potential sales of approved products. Additionally, the company may receive research grants and funding from governmental or non-governmental organizations to support its R&D activities.

XTL Biopharmaceuticals Sponsored ADR Financial Statement Overview

Summary
XTL Biopharmaceuticals Ltd. faces ongoing financial headwinds, with significant net losses and negative EBIT margins. Despite a slight improvement in stockholders' equity, the company struggles with high liabilities and negative cash flows, reflecting operational inefficiencies typical in the biotech sector.
Income Statement
20
Very Negative
The income statement reflects significant challenges with persistent net losses and negative EBIT margins due to the absence of revenue. The company's profitability trajectory is concerning, with inconsistent net income figures over the years. The lack of revenue growth further exacerbates the financial instability, indicating potential operational inefficiencies in the biotechnology sector.
Balance Sheet
40
Negative
The balance sheet shows a slight improvement in stockholders' equity, moving from negative to positive in the most recent year. However, the overall financial stability remains weak due to high liabilities relative to assets. The company benefits from a low debt profile, but the equity ratio indicates a fragile financial structure that may pose risks in sustaining operations.
Cash Flow
30
Negative
The cash flow statement reveals consistent negative free cash flow and operating cash flow, highlighting liquidity challenges. The cash flow to net income ratios indicate inefficiencies in converting net losses to positive cash flow. Although there is some improvement in cash flow from investing activities, the overall cash flow management remains a concern.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue162.00K451.00K0.000.000.000.00
Gross Profit162.00K3.00K0.000.000.000.00
EBITDA-865.75K-930.00K-764.00K-879.00K-1.03M-947.00K
Net Income-1.06M-1.03M-1.78K-1.35M435.00K-782.00K
Balance Sheet
Total Assets12.43M8.55M2.43M4.19M6.62M6.50M
Cash, Cash Equivalents and Short-Term Investments5.06M1.14M2.01M3.72M6.13M6.04M
Total Debt0.00138.00K0.000.000.000.00
Total Liabilities236.00K3.12M206.00K187.00K1.28M254.00K
Stockholders Equity12.20M5.43M2.22M4.00M5.33M6.25M
Cash Flow
Free Cash Flow0.00-1.67M-707.00K-901.00K-1.05M-851.00K
Operating Cash Flow0.00-1.62M-707.00K-901.00K-1.05M-850.00K
Investing Cash Flow0.00-844.00K41.00K36.00K8.00K32.00K
Financing Cash Flow0.001.45M0.000.00385.00K0.00

XTL Biopharmaceuticals Sponsored ADR Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.20
Price Trends
50DMA
1.22
Negative
100DMA
1.26
Negative
200DMA
1.60
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
51.42
Neutral
STOCH
36.43
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XTLB, the sentiment is Neutral. The current price of 1.2 is above the 20-day moving average (MA) of 1.17, below the 50-day MA of 1.22, and below the 200-day MA of 1.60, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 51.42 is Neutral, neither overbought nor oversold. The STOCH value of 36.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XTLB.

XTL Biopharmaceuticals Sponsored ADR Risk Analysis

XTL Biopharmaceuticals Sponsored ADR disclosed 38 risk factors in its most recent earnings report. XTL Biopharmaceuticals Sponsored ADR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

XTL Biopharmaceuticals Sponsored ADR Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.50B0.32-61.87%2.27%17.10%1.59%
45
Neutral
$14.04M10.2411.34%-99.76%76.96%
44
Neutral
$8.37M-214.79%52.82%
EQEQ
41
Neutral
$11.25M-88.32%-19.76%-13.20%
41
Neutral
$15.00M-105.79%-82.54%-12.53%
40
Underperform
$15.36M-106.05%9.46%
39
Underperform
$10.72M-26.83%86.44%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XTLB
XTL Biopharmaceuticals Sponsored ADR
1.20
-1.10
-47.83%
SYBX
Synlogic
1.20
-0.27
-18.37%
MBRX
Moleculin Biotech
0.35
-3.14
-89.97%
COCP
Cocrystal Pharma
1.51
-0.87
-36.55%
EQ
Equillium
0.32
-0.36
-52.94%
HOOK
Hookipa Pharma
1.23
-4.42
-78.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 13, 2024